UCB Promotes 'Underappreciated' Pipeline In FY Results
Executive Summary
UCB's pipeline will see advances across multiple therapy areas in 2018, including more emphasis on new epilepsy indications and unmet needs in neurodegenerative diseases like Alzheimer's.